| Formulation |
The EEF1G solution (1mg/ml) contains 20mM Tris-HCl buffer (pH 8.0), 0.15M NaCl, 10% glycerol and 1mM DTT. |
| Purity |
Greater than 90% as determined by SDS-PAGE. |
| Description |
EEF1G Human Recombinant produced in E.coli is a single, non-glycosylated polypeptide chain containing 460 amino acids (1-437) and having a molecular mass of 52.5 kDa.EEF1G is fused to a 23 amino acid His-Tag at N-terminus and purified by proprietary chromatographic techniques. |
| Protein Background |
Eukaryotic Translation Elongation Factor 1 Gamma (EEF1G) takes part in anchoring the complex to additional cellular components. EEF1G is a multi-protein complex which is in charge of the delivery of aminoacyl-tRNAs to the ribosome. Over expression of EEF1G is linked with pancreatic cancer, due to the role of EEF1G protein in the oncogenic transformation process. |
| Expression host |
E.coli. |
| Synonyms |
EF1G, GIG35, Elongation factor 1-gamma, Eukaryotic Translation Elongation Factor 1 Gamma, EEF1G, EF-1-gamma, eEF-1B gamma, PRO1608. |
| Reagent Appearance |
Sterile Filtered colorless solution. |
| Stability |
Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).Avoid multiple freeze-thaw cycles. |
| Amino acid sequence |
MGSSHHHHHH SSGLVPRGSH MGSMAAGTLY TYPENWRAFK ALIAAQYSGA QVRVLSAPPH FHFGQTNRTP EFLRKFPAGK VPAFEGDDGF CVFESNAIAY YVSNEELRGS TPEAAAQVVQ WVSFADSDIV PPASTWVFPT LGIMHHNKQA TENAKEEVRR ILGLLDAYLK TRTFLVGERV TLADITVVCT LLWLYKQVLE PSFRQAFPNT NRWFLTCINQ PQFRAVLGEV KLCEKMAQFD AKKFAETQPK KDTPRKEKGS REEKQKPQAE RKEEKKAAAP APEEEMDECE QALAAEPKAK DPFAHLPKST FVLDEFKRKY SNEDTLSVAL PYFWEHFDKD GWSLWYSEYR FPEELTQTFM SCNLITGMFQ RLDKLRKNAF ASVILFGTNN SSSISGVWVF RGQELAFPLS PDWQVDYESY TWRKLDPGSE ETQTLVREYF SWEGAFQHVG KAFNQGKIFK. |
| Antibody Properties |
It is recommended to add 100ul of deionized water and let the lyophilized pellet dissolve completely. Slight turbidity may occur after reconstitution, which doesn't affect the activity of the ERBB2 antibody. The solution can be clarified by centrifugation. |
| Stability/Storage |
MTQVCTGTDM KLRLPASPET HLDMLRHLYQ GCQVVQGNLE LTYLPTNASL SFLQDIQEVQ GYVLIAHNQV RQVPLQRLRI TQVCTGTDM KLRLPASPET HLDMLRHLYQ GCQVVQGNLE LTYLPTNASL SFLQDIQEVQ GYVLIAHNQV RQVPLQRLRI VRGTQLFEDN YALAVLDNGD PLNNTTPVTG ASPGGLRELQ LRSLTEILKG GVLIQRNPQL CYQDTILWKD IFHKNNQLAL TLIDTNRSRA CHPCSPMCKG SRCWGESSED CQSLTRTVCA GGCARCKGPL PTDCCHEQCA AGCTGPKHSD CLACLHFNHS GICELHCPAL VTYNTDTFES MPNPEGRYTF GASCVTACPY NYLSTDVGSC TLVCPLHNQE VTAEDGTQRC EKCSKPCARG THSLPPRPAA VPVPLRMQPG PAHPVLSFLR PSWDLVSAFY SLPLAPLSPT SVPISPVSVG RGPDPDAHVA VDLSRYEG. |
| Patent Rights |
The lyophilized antibody remains stable and fully active when stored at -20°C. It is recommended to aliquot the product after reconstitution to avoid repeated freezing/thawing cycles and store frozen at -80°C. The Reconstituted antibody can be stored at 4°C for a limited period of time; it does not show decline in activity after one week at 4°C. |
| Antibody Content |
The ERBB2 antibody reacts with an epitope located on Human ERBB2 - without the last 79 amino acid residues. |
